Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, patients who underwent Roux-en-Y gastric bypass surgery lost significant weight and improved obesity-related complications, but experienced increased hair loss and needed careful calcium and protein management.

This study found that topical finasteride and flutamide both significantly reduced sebaceous gland growth and decreased prostatic weights in hamsters, indicating systemic effects despite local application.

This study found that six months after bariatric surgery, Latvian patients experienced significant improvements in quality of life, weight loss, and resolution of some obesity-related symptoms, although hair loss was a common postoperative effect.

Cyproterone acetate therapy improved hair loss and reduced testosterone levels in a menopausal woman.

This study found that bariatric surgery effectively treated morbid obesity and improved quality of life and the resolution of comorbidities for most patients.

This article discusses polycystic ovarian syndrome and highlights the importance of early diagnosis and management to reduce long-term complications, but reports no new research findings.

This case study reported a 40-year-old woman developing Cushing Syndrome months after a single intraarticular injection of Triamcinolone Acetonide, highlighting the potential long-term effects of corticosteroid exposure and the importance of awareness about these risks for clinicians and patients.

This article discusses the fragmented approach to PCOS treatment, highlighting the recent recognition that insulin resistance is a common, intrinsic feature in most women with PCOS.

This review discusses the symptoms, causes, and treatment options for polycystic ovary syndrome and reports no new results; the authors highlight the role of lifestyle changes, medications, and fertility treatments.

This study found that Sri Lankan women with polycystic ovary syndrome experienced higher psychological distress and poorer health-related quality of life, primarily linked to hirsutism rather than obesity.

This review discusses strategies for managing hirsutism in PCOS, highlighting lifestyle changes, hormonal treatments, and the importance of patient-centered care, but reports no new clinical results.

This study found that a combination of low-dose flutamide and metformin therapy may reverse insulin resistance and reduce fat mass in nonobese adolescents with PCOS.

In this study, men using 2% and 5% minoxidil solutions experienced a significant increase in hair weight for 96 weeks compared to placebo, with effects diminishing after treatment cessation.

This review discusses potential treatments for androgen excess in polycystic ovary syndrome and reports no new findings, emphasizing the importance of individualized antiandrogenic management to minimize side effects.

This paper discusses polycystic ovary syndrome with a focus on androgen excess as the primary symptom and notes that insulin resistance may contribute to it in many patients, but provides no new research findings.

In this study, finasteride, 1 mg daily, significantly increased hair weight more than hair count in men with androgenetic alopecia, indicating additional factors like hair growth rate and thickness may contribute to its effectiveness.

This review examines the evaluation and management of hirsutism and hyperandrogenism in postmenopausal women and reports no new clinical findings.

This review discusses the forms of selenium and sulfur in soil, their plant absorption, and risks of toxicity to livestock, emphasizing selenium's role in selenosis and sulfur's link to polioencephalomalacia in ruminants; it reports no new experimental results.

In this study from IJIRT, researchers evaluated teaching programs focused on enhancing waste management knowledge among women, assessing the effectiveness of these educational initiatives.

This study found a high prevalence of clinical signs and functional disorders of androgen excess in premenopausal women, with idiopathic hyperandrogenism and idiopathic hirsutism rates similar to PCOS.

This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.

In this study, polycystic ovary syndrome was the most prevalent cause of androgen excess, and suppressive hormonal therapy improved hirsutism, menstrual dysfunction, and acne in most patients, though side effects were common.

This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.

This review discusses the hypothesis that polycystic ovary syndrome may originate in fetal life due to prenatal androgen exposure, but reports no new clinical results.

This study found that women with polycystic ovary syndrome have higher rates of nonalcoholic fatty liver disease, with androgen excess contributing to the risk.

This article outlines the clinical features, evaluation, and treatment strategies for androgen excess in polycystic ovary syndrome, highlighting important diagnostic and management approaches but reporting no new research results.

This review offers evidence-based recommendations for diagnosing and treating female pattern hair loss, emphasizing clinical assessment and starting treatment with minoxidil, while noting that measurement of certain hormones and vitamins is optional.

This study suggests that although the G972R variant of the IRS1 gene might increase AA excess risk in heterozygous carriers with CYP21 mutations, both variations play a limited role in PCOS development.

This study found that serum vaspin levels were elevated in women with polycystic ovary syndrome compared to controls, but treatment with metformin or weight loss did not significantly change these levels.

This study established a mouse model for Cushing's syndrome due to a specific Crh mutation, which may help explore the effects of glucocorticoid excess and evaluate treatments for corticosteroid-induced osteoporosis.